Clinical Trial: A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma
Brief Summary: A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Merck Sharp & Dohme Corp.
Dates:
Date Received: December 23, 2004
Date Started: February 2005
Date Completion:
Last Updated: May 25, 2015
Last Verified: May 2015